SIREN : 401973730
PHARMAGENCE is a French company founded 30 years ago, specialized in the sector Agences immobilières. Based in PARIS (75017), this company of category PME shows in 2024 a net income negative of -106 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-11
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | -106 284 € | 165 507 € | -123 032 € | 10 258 € | 119 710 € | 110 528 € | -85 201 € |
| EBITDA | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, PHARMAGENCE records a net loss of 106 k€. This deficit will reduce equity on the balance sheet.
-106 284 €
The debt ratio (= Financial debt / Equity x 100) stands at 15%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
14.997%
79.621%
91.2%
In 2024, the debt ratio of PHARMAGENCE (15.00) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMAGENCE (79.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
The liquidity ratio (= Current assets / Current liabilities) stands at 591.66. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
591.66
In 2024, the liquidity ratio of PHARMAGENCE (591.66) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Compare PHARMAGENCE with other companies in the same sector:
Voir toutes les statistiques du secteur Agences immobilières
The revenue of PHARMAGENCE is not publicly disclosed (confidential accounts filed with INPI).
PHARMAGENCE recorded a net loss in 2024.
The headquarters of PHARMAGENCE is located in PARIS (75017), in the department Paris.
The tax return of PHARMAGENCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMAGENCE operates in the sector Agences immobilières (NAF code 68.31Z). See the 'Sector positioning' section above to compare the company with its competitors.